Session: 262. HIV: Antiretroviral Therapy, Saturday, 12:15-1:30 p.m.
Background : Adherence to antiretroviral therapy (ART) to treat HIV remains a critical global health challenge given its relationship with individual health outcomes and population-level transmission. Given barriers associated with oral ART adherence, and considerations of patients’ preferences, long-acting injectable (LA) ART (Cabotegravir + Rilpivirine) is under development and has been shown to be non-inferior to daily oral ART in Phase III trials. While most of the trial participants have been men, as LA ART gets closer to becoming available for routine clinical use, it is critical to understand how this option is perceived by women.
Methods : We conducted in-depth interviews with 67 individuals, 53 people living with HIV (PLHIV) and 14 health care providers, in 11 sites in the United States and Spain participating in Phase III LA ART trials (ATLAS, ATLAS 2-M and FLAIR). Twenty percent (10/53) of trial participants interviewed were women. Interviews explored patient and provider perspectives and experiences with LA ART, and appropriate candidates and recommendations to support use. Interviews were audio-recorded, transcribed and coded using thematic content analysis.
Results : Overall, several salient themes emerged regarding participant’s generally positive experiences transitioning from daily oral ART to injectable ART including: the importance of the clinical efficacy of LA ART, the ability to learn to manage injection side-effects over time, and the “freedom” reportedly afforded by LA ART logistically and psychosocially. Women interviewed shared many of the aforementioned positive perceptions of LA ART but also had some unique perspectives. Female participants discussed how LA ART was easier to integrate into their daily lives including managing their multiple roles and responsibilities, which often involved working full-time and taking care of themselves as well as their family and children.
Conclusion : Similar to all participants, female participants had generally positive views of LA ART. However, the gendered nature of their daily lives also led to some unique perspectives on why and how they were satisfied with LA ART that merits further exploration in future research.
Wendy Davis– Research Associate Professor, American University, Washington, D.C., DC
Andrea Mantsios– Consultant, Johns Hopkins Bloomberg School of Public Health, New York, NY
Miranda Murray– Head, ViiV Healthcare, Brentford, England, United Kingdom
Tahilin Sanchez Karver– Doctoral Student, Johns Hopkins University, Baltimore, MD
David Margolis– Director of HIV Drug Development, ViiV Healthcare, Research Triangle Park, NC
Princy Kumar– Professor, Medicine; Chief, Division of Infectious Diseases and Travel Medicine, Georgetown University School of Medicine, Washington, DC
Susan Swindells– Professor, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE
Fritz Bredeek– Infectious Disease Specialist, Metropolis Medical, San Francisco, CA
Miguel García Deltoro– Head of Infectious Diseases, General Hospital of Valencia, Valencia, Comunidad Valenciana, Spain
Rafael Rubio García– Professor, Medicine, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
Antonio Antela– Atending Physician, Hospital Clínico Universitario de santiago de Compostela, Spain, Coruna, Galicia, Spain
Cindy Garris– Director, ViiV Healthcare, Raleigh, NC
Mark Shaefer– Global Medical Lead, Cabotegravir, ViiV Healthcare, Chapel Hill, NC
Santiago Cenoz Gomis– Medical Manager, ViiV Healthcare, Madrid, Madrid, Spain
Miguel Pascual Bernaldez– Local Senior Study Manager, GSK, Madrid, Madrid, Spain
Deanna Kerrigan– Professor, Sociology; Director, Center for Health, Risk and Society, American University, Washington, D.C., DC